Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

被引:9
|
作者
Fuso, L [1 ]
Amant, E [1 ]
Neven, P [1 ]
Berteloot, P [1 ]
Vergote, I [1 ]
机构
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Obstet & Gynecol, Div Gynecol Oncol, Louvain, Belgium
关键词
ovarian cancer; ovarian; neoplasms; therapy; chemotherapy; paclitaxel; carboplatin; gemcitabine;
D O I
10.1111/j.1525-1438.2006.00315.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Single-agent gemcitabine demonstrated response rates of 11-60% in platinum/paclitaxel-resistant ovarian cancer. Twenty-four patients with epithelial ovarian cancer were treated with gemcitabine 800 mg/m(2) on days 1 and 8, carboplatin area under the curve 5 on day 1, and paclitaxel 175 mg/m(2) over 3 h on day 1 every 3 weeks for six cycles. Median age was 54 years, and FIGO stage distribution was IIC, 1 patient, III, 18, and IV, 5. A total of 22 (92%) patients completed all the six planned courses of chemotherapy. Doses were reduced in 8 out of 24 (33%) patients. Of the 17 patients with measurable disease, 15 underwent an interval debulking surgery. Prior to interval debulking surgery, all 15 patients had a partial response according to the response evaluation criteria in solid tumors criteria. Overall in the 17 patients with measurable disease, the response rate at the end of the first-line chemotherapy (including interval debulking) was 94% (14 [82%] complete response and 2 [12%], partial response). One patient (6%) received only one cycle due to early progression. Using the CA125 criteria as defined by the Gynecologic Cancer Intergroup, all patients had at least a partial response prior to interval debulking, and the overall response rate of the whole first-line chemotherapy and interval debulking (n = 15) was observed in 21 out of 23 patients (91%). The dose-limiting toxicity was bone marrow toxicity. Median overall survival was 28 months, and the 2-year actuarial survival was 73%. The gemcitabine, carboplatin, paclitaxel triplet has an acceptable toxicity with high response rates as first-line therapy in advanced ovarian cancer.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 50 条
  • [31] Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer
    Meerpohl, HG
    duBois, A
    Kuhnle, H
    Luck, HJ
    Kreienberg, R
    Mobus, V
    Bauknecht, T
    Kochli, O
    Bochtler, H
    Diergarten, K
    Heuser, A
    SEMINARS IN ONCOLOGY, 1995, 22 (06) : 7 - 12
  • [32] Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder
    Smith, David C.
    Mackler, Niklas J.
    Dunn, Rodney L.
    Hussain, Maha
    Wood, David
    Lee, Cheryl T.
    Sanda, Martin
    Vaishampayan, Ulka
    Petrylak, Daniel P.
    Quinn, David I.
    Beekman, Kathleen
    Montie, James E.
    JOURNAL OF UROLOGY, 2008, 180 (06): : 2384 - 2388
  • [33] Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin
    Terakawa, Tomoaki
    Miyake, Hideaki
    Yokoyama, Naoki
    Miyazaki, Akira
    Tanaka, Hiroyuki
    Inoue, Takaaki
    Fujisawa, Masato
    UROLOGIA INTERNATIONALIS, 2014, 92 (02) : 180 - 185
  • [34] Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer - A multicenter phase II trial
    Potamianou, A
    Androulakis, N
    Papakotoulas, P
    Toufexi, H
    Latoufis, C
    Kouroussis, C
    Christofilakis, C
    Xenidis, N
    Georgoulias, V
    Polyzos, A
    ONCOLOGY, 2005, 69 (04) : 348 - 353
  • [35] Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study
    Marth, C.
    Windbichler, G. H.
    Hausmaninger, H.
    Petru, E.
    Estermann, K.
    Pelzer, A.
    Mueller-Holzner, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (04) : 1522 - 1528
  • [36] Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: A phase I trial
    Meerpohl, HG
    duBois, A
    Luck, HJ
    Kuhnle, H
    Mobus, V
    Kreienberg, R
    Bauknecht, T
    Kochli, O
    Bochtler, H
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S17 - S22
  • [37] A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)
    Wang, Zhen
    Huang, Cheng
    Yang, Jin-Ji
    Song, Yong
    Cheng, Ying
    Chen, Gong-Yan
    Yan, Hong-Hong
    Ben, Xiao-Song
    Wang, Bin-Chao
    Xu, Chong-Rui
    Jiang, Ben-Yuan
    Zhou, Qing
    Chen, Hua-Jun
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 183 - 191
  • [38] Sequentially insert of carboplatin followed by Paclitaxel in the first-line therapy for ovarian cancer carboplatin followed by Paclitaxel in the therapy for ovarian cancer
    Sehouli, J.
    Mustea, A.
    Pfisterer, J.
    Camara, O.
    Lichtenegger, W.
    Oskay-Oezcelik, G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S70 - S70
  • [39] Paclitaxel, carboplatin, and hexamethylmelamine (taxchex) as first-line therapy for ovarian cancer
    Hartenbach, EM
    Harris, LS
    Bailey, HH
    Grosen, EA
    Larrison, E
    Chen, D
    Twiggs, LB
    Schink, JC
    CANCER JOURNAL, 1999, 5 (06): : 348 - 355
  • [40] A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
    Perez, EA
    Hillman, DW
    Stella, PJ
    Krook, JE
    Hartmann, LC
    Fitch, TR
    Hatfield, AK
    Mailliard, JA
    Nair, S
    Kardinal, CG
    Ingle, JN
    CANCER, 2000, 88 (01) : 124 - 131